Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.

Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, Firestein R, Latham S, Sampath D, Evangelista M, Hatzivassiliou G.

Cell Metab. 2018 Sep 4;28(3):383-399.e9. doi: 10.1016/j.cmet.2018.06.003. Epub 2018 Jun 28.

PMID:
30043751
2.

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.

Bhakta S, Crocker LM, Chen Y, Hazen M, Schutten MM, Li D, Kuijl C, Ohri R, Zhong F, Poon KA, Go MAT, Cheng E, Piskol R, Firestein R, Fourie-O'Donohue A, Kozak KR, Raab H, Hongo JA, Sampath D, Dennis MS, Scheller RH, Polakis P, Junutula JR.

Mol Cancer Ther. 2018 Mar;17(3):638-649. doi: 10.1158/1535-7163.MCT-17-0813. Epub 2017 Dec 27.

PMID:
29282299
3.

Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.

Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt AN, Tinianow JN, Gupta N, Li D, Firestein R, Marik J, Scales SJ, Williams SP.

Mol Cancer Ther. 2017 Jan;16(1):134-142. doi: 10.1158/1535-7163.MCT-16-0449. Epub 2016 Oct 19.

4.

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition.

Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson L, Vanderbilt A, Williams S, Daemen A, Belvin M, Eigenbrot C, Jackson PK, Malek S, Hatzivassiliou G, Sampath D, Evangelista M, O'Brien T.

Nat Chem Biol. 2016 Oct;12(10):779-86. doi: 10.1038/nchembio.2143. Epub 2016 Aug 1.

PMID:
27479743
5.

Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.

Bergeron P, Koehler MF, Blackwood EM, Bowman K, Clark K, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Ramaswamy S, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini M.

ACS Med Chem Lett. 2016 Apr 5;7(6):595-600. doi: 10.1021/acsmedchemlett.6b00044. eCollection 2016 Jun 9.

6.

ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.

Williams SP, Ogasawara A, Tinianow JN, Flores JE, Kan D, Lau J, Go M, Vanderbilt AN, Gill HS, Miao L, Goldsmith J, Rubinfeld B, Mao W, Firestein R, Yu SF, Marik J, Terwisscha van Scheltinga AG.

Oncotarget. 2016 May 3;7(18):25103-12. doi: 10.18632/oncotarget.8390.

7.

Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.

Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini MH.

ACS Med Chem Lett. 2016 Jan 6;7(3):223-8. doi: 10.1021/acsmedchemlett.5b00278. eCollection 2016 Mar 10.

8.

Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.

Storm EE, Durinck S, de Sousa e Melo F, Tremayne J, Kljavin N, Tan C, Ye X, Chiu C, Pham T, Hongo JA, Bainbridge T, Firestein R, Blackwood E, Metcalfe C, Stawiski EW, Yauch RL, Wu Y, de Sauvage FJ.

Nature. 2016 Jan 7;529(7584):97-100. doi: 10.1038/nature16466. Epub 2015 Dec 23.

PMID:
26700806
9.

Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.

Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C, Eastham-Anderson J, Singh M, Vij R, Hongo JA, Firestein R, Schutten M, Flagella K, Polakis P, Polson AG.

Sci Transl Med. 2015 Nov 18;7(314):314ra186. doi: 10.1126/scitranslmed.aac7433.

PMID:
26582901
10.

Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis.

McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa e Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R.

J Pathol. 2015 Dec;237(4):508-19. doi: 10.1002/path.4596. Epub 2015 Sep 24.

PMID:
26235356
11.

Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.

Lin K, Rubinfeld B, Zhang C, Firestein R, Harstad E, Roth L, Tsai SP, Schutten M, Xu K, Hristopoulos M, Polakis P.

Clin Cancer Res. 2015 Nov 15;21(22):5139-50. doi: 10.1158/1078-0432.CCR-14-3383. Epub 2015 Jul 8.

12.

Castration-resistant Lgr5(+) cells are long-lived stem cells required for prostatic regeneration.

Wang BE, Wang X, Long JE, Eastham-Anderson J, Firestein R, Junttila MR.

Stem Cell Reports. 2015 May 12;4(5):768-79. doi: 10.1016/j.stemcr.2015.04.003. Epub 2015 Apr 30.

13.

An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.

Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, Desai R, Raja R, Friedman BA, Haverty PM, Polakis P, Firestein R.

Clin Cancer Res. 2015 Jul 15;21(14):3252-62. doi: 10.1158/1078-0432.CCR-15-0156. Epub 2015 Apr 10.

14.

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C, Wang Y.

Clin Cancer Res. 2015 Jul 1;21(13):2941-51. doi: 10.1158/1078-0432.CCR-14-3111. Epub 2015 Apr 2.

15.

HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin.

Yu N, Kakunda M, Pham V, Lill JR, Du P, Wongchenko M, Yan Y, Firestein R, Huang X.

Mol Cell Biol. 2015 Apr;35(8):1390-400. doi: 10.1128/MCB.01307-14. Epub 2015 Feb 2.

16.

An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.

Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, Zhang Y, Ingle GS, Fourie-O'Donohue A, Kozak KR, Ross S, Dennis MS, Spencer SD.

Mol Cancer Ther. 2014 Nov;13(11):2630-40. doi: 10.1158/1535-7163.MCT-14-0487-T. Epub 2014 Sep 23.

17.

Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.

Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, Yuan W, Ha C, Gilbert HN, Reeder J, Pau G, Stinson J, Stern HM, Manning G, Wu TD, Neve RM, de Sauvage FJ, Modrusan Z, Seshagiri S, Firestein R, Zhang Z.

Nat Commun. 2014 May 8;5:3830. doi: 10.1038/ncomms4830.

18.

An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth.

Adler AS, McCleland ML, Yee S, Yaylaoglu M, Hussain S, Cosino E, Quinones G, Modrusan Z, Seshagiri S, Torres E, Chopra VS, Haley B, Zhang Z, Blackwood EM, Singh M, Junttila M, Stephan JP, Liu J, Pau G, Fearon ER, Jiang Z, Firestein R.

Genes Dev. 2014 May 15;28(10):1068-84. doi: 10.1101/gad.237206.113. Epub 2014 May 1.

19.

Oncogenic ERBB3 mutations in human cancers.

Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S.

Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Erratum in: Cancer Cell. 2014 Apr 14;25(4):543-4.

20.

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M.

Cancer Res. 2013 May 15;73(10):3132-44. doi: 10.1158/0008-5472.CAN-12-4562. Epub 2013 Mar 28.

Supplemental Content

Loading ...
Support Center